Alloy Therapeutics provides foundational biologics discovery technologies and services, including antibody and TCR discovery, to academic and biotech partners. By democratizing access to these platforms, the company enables researchers to efficiently develop therapeutics that address complex disease challenges.
Funding
$134M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
The development of novel therapeutics is often hindered by limited access to diverse and robust biologics discovery platforms, particularly for academic and smaller biotech entities. Traditional antibody and T-cell receptor (TCR) discovery processes can be expensive, time-consuming, and require specialized expertise, creating a barrier to entry for many researchers.
Solution
Alloy Therapeutics addresses these challenges by providing access to foundational biologics discovery technologies and services, including antibody and TCR discovery, to a broad range of partners. The company offers both bespoke discovery campaigns and platform licensing, enabling researchers to efficiently develop therapeutics across multiple modalities. Alloy's platforms include transgenic mice for fully human antibody discovery, a TCR discovery service, and a platform for creating optimized antisense oligonucleotides (ASOs). By reinvesting 100% of its revenue into innovation, Alloy continuously expands its technology offerings and ensures its partners have access to cutting-edge tools.
Target Audience
Alloy Therapeutics serves academic scientists, small to medium-sized biotech companies, and large biopharmaceutical organizations seeking to discover and develop novel therapeutics.
Features
- ATX-Gx™ Transgenic Mice: Fully human in vivo antibody discovery platform with exceptional strain diversity, including hyperimmune mice and common light-chain (CLC) strains for bispecific development.
- Keyway™ TCR Discovery: Fully integrated platform and service for discovering novel immunotherapies by pairing antibody discovery expertise with soluble T cell receptor (TCR) therapeutics.
- AntiClastic™ ASO Format: Proprietary technology for creating optimized antisense oligonucleotides (ASOs) with improved potency, safety, and scalability.
- Antibody Discovery Services: End-to-end antibody and bispecific discovery services, including AI/ML-powered clone selection and robust testing for binding, developability, and function.
- Bispecific Discovery: Integrated workflow from drug concept to bispecific lead, including antibody discovery, bispecific format engineering, and functional screening.
- Antibody Optimization: Advanced antibody optimization workflows and strategies, including AI/ML-powered in silico design and high-throughput expression and testing.